Loading
Tests whether adding the DLL3 T-cell engager to first-line maintenance can push median survival in extensive-stage disease past two years, as the phase 1b hinted.
Builds on DeLLphi-303 (phase 1b), where tarlatamab plus a PD-L1 inhibitor as first-line maintenance gave median OS 25.3 months and PFS 5.6 months. On 8 September 2026 Amgen and AstraZeneca announced that the trial met its primary overall survival endpoint at the pre-specified interim analysis, with statistically significant gains in progression-free survival and response rate; detailed figures are held for a congress presentation. A parallel phase 3 (DeLLphi-312) adds tarlatamab to induction chemo-immunotherapy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
563 enrolled.
Met at the pre-specified interim analysis: Amgen's 8 September 2026 release describes a statistically significant and clinically meaningful improvement; medians and hazard ratio not yet disclosed, detailed data promised for an upcoming congress
SourceStatistically significant and clinically meaningful improvement per the sponsor; figures not yet public
SourceStatistically significant improvement per the sponsor; figures not yet public
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Tarlatamab + durvalumab maintenance | - | Met at the pre-specified interim analysis: Amgen's 8 September 2026 release describes a statistically significant and clinically meaningful improvement; medians and hazard ratio not yet disclosed, detailed data promised for an upcoming congress | - | - | link |
| Durvalumab maintenance | - | - | ||||
| Progression-free survival | Tarlatamab + durvalumab maintenance | - | Statistically significant and clinically meaningful improvement per the sponsor; figures not yet public | - | - | link |
| Durvalumab maintenance | - | - | ||||
| Objective response rate | Tarlatamab + durvalumab maintenance | - | Statistically significant improvement per the sponsor; figures not yet public | - | - | link |
| Durvalumab maintenance | - | - |
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).
Shares A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC), DLL3, Tarlatamab, Amgen.
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.